![]() |
|
|
Departments of Pharmacology and Toxicology (G.B.J.S., L.L.B., T.E.M.), Surgery (K.R.R., D.P.), and Medicine (T.E.M.), and School of Environmental Studies (T.E.M.), Queen's University, Kingston, Ontario, Canada; and Department of Pharmacology and Toxicology (J.R.B.), University of Western Ontario, London, Ontario, Canada
The contributions of different enzymes to
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) biotransformation were
assessed in human lung microsomes prepared from peripheral lung specimens
obtained from seven subjects. Metabolite formation was expressed as a
percentage of total recovered radioactivity from [5-3H]NNK and its
metabolites per milligram of protein per minute.
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol was the major metabolite formed
in the presence of an NADPH-generating system, with production ranging from
0.5186 to 1.268%/mg of protein/min, and total NNK bioactivation (represented
by the sum of the four
-carbon hydroxylation endpoint metabolites)
ranged from 0.002100 to 0.005685%
-hydroxylation/mg of protein/min.
Overall, production of bioactivation metabolites was greater than that of
detoxication (i.e., N-oxidation) products. Based on total
bioactivation, subjects could be classified as high or low NNK bioactivators.
In the presence of an NADPH-generating system, microsomal formation of the
endpoint metabolite 1-(3-pyridyl)-1-butanone-4-carboxylic acid (keto acid) was
consistently higher than that of all other
-carbon hydroxylation
endpoint metabolites. Contributions of cytochrome P450 (P450) enzymes to NNK
oxidation were demonstrated by NADPH dependence, inhibition by carbon
monoxide, and inhibition by the nonselective P450 inhibitors proadifen
hydrochloride (SKF-525A) and 1-aminobenzotriazole (ABT), particularly in lung
microsomes from high bioactivators. At 5.0 mM, ABT inhibited total NNK
bioactivation by 54 to 100%, demonstrating the importance of ABT-sensitive
enzyme(s) in human pulmonary NNK bioactivation. Contributions of CYP2A6 and/or
CYP2A13, as well as CYP2B6, to NNK bioactivation were also suggested by
selective chemical and antibody inhibition in lung microsomes from some
subjects. It is likely that multiple P450 enzymes contribute to human
pulmonary microsomal NNK bioactivation, and that these contributions vary
between individuals.
This article has been cited by other articles:
![]() |
X. Zhang, J. D'Agostino, H. Wu, Q.-Y. Zhang, L. von Weymarn, S. E. Murphy, and X. Ding CYP2A13: Variable Expression and Role in Human Lung Microsomal Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 570 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Brown, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey Analysis of CYP2A Contributions to Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Peripheral Lung Microsomes Drug Metab. Dispos., November 1, 2007; 35(11): 2086 - 2094. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Lee and R. F. Tyndale Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment J Psychopharmacol, July 1, 2006; 20(4_suppl): 7 - 14. [Abstract] [PDF] |
||||
![]() |
U. Breyer-Pfaff, H.-J. Martin, M. Ernst, and E. Maser ENANTIOSELECTIVITY OF CARBONYL REDUCTION OF 4-METHYLNITROSAMINO-1-(3-PYRIDYL)-1-BUTANONE BY TISSUE FRACTIONS FROM HUMAN AND RAT AND BY ENZYMES ISOLATED FROM HUMAN LIVER Drug Metab. Dispos., September 1, 2004; 32(9): 915 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Boland, C. Y. Lin, D. Morin, L. Miller, C. Plopper, and A. Buckpitt Site-Specific Metabolism of Naphthalene and 1-Nitronaphthalene in Dissected Airways of Rhesus Macaques J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 546 - 554. [Abstract] [Full Text] [PDF] |
||||